3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
34
Melanoma
13
Carcinoma, Hepatocellular
13
Neoplasm Metastasis
12
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Neoplasms
9
Esophageal Neoplasms
9
Colorectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
5
Breast Neoplasms
5
Recurrence
4
Rectal Neoplasms
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Liver Neoplasms
3
Head and Neck Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Radiation Pneumonitis
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neuroblastoma
2
Interventions
Nivolumab
3
Cisplatin
2
Albumin-Bound Paclitaxel
2
tislelizumab
1
spartalizumab
1
Taxes
1
Standard of Care
1
Radiotherapy
1
Immunotherapy
1
Gemcitabine
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Muscle-Invasive Bladder Carcinoma
×
Immunotherapy
×
Clear all
NCT04724928
2025-01-15
EFFORT-MIBC
University Hospital, Ghent
Phase 2
Recruiting
156 enrolled